Grifols (NASDAQ:GRFS) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $8.72 and traded as high as $9.90. Grifols shares last traded at $9.86, with a volume of 338,734 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GRFS shares. Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th. Finally, Zacks Research upgraded Grifols to a "hold" rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, Grifols currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.30.

Grifols Stock Performance

The firm has a fifty day moving average of $10.13 and a 200-day moving average of $8.72. The firm has a market cap of $6.78 billion, a P/E ratio of 8.43, a PEG ratio of 0.34 and a beta of 0.64. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20.

Grifols Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's dividend payout ratio (DPR) is presently 11.97%.

Institutional Trading of Grifols

Institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc acquired a new stake in Grifols during the 1st quarter worth $28,000. EverSource Wealth Advisors LLC grew its stake in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock worth $74,000 after purchasing an additional 4,604 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Grifols during the second quarter worth $95,000. R Squared Ltd acquired a new stake in shares of Grifols during the second quarter worth $95,000. Finally, Ballentine Partners LLC bought a new position in Grifols during the first quarter worth about $77,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.